Omnia Family Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Omnia Family Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25	Closed	-$5K	–	514
2019 Q1	$5K	Buy	+25	New	+$4.62K	﹤0.01%	323
2018 Q2	–	Sell	-18	Closed	-$3K	–	618
2018 Q1	$3K	Buy	+18	New	+$2.94K	﹤0.01%	388
2017 Q1	–	Sell	-21	Closed	-$2K	–	778
2016 Q4	$2K	Buy	+21	New	+$1.71K	﹤0.01%	631

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Omnia Family Wealth's VRTX Position: Q2 2019 in Review

Omnia Family Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 25 shares — an estimated $5K sold.

Omnia Family Wealth first reported a position in VRTX in Q4 2016 and held it in 3 quarters. The position peaked at $5K in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Omnia Family Wealth reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Omnia Family Wealth sold 25 Vertex Pharmaceuticals shares in Q2 2019, an estimated $5K.
Omnia Family Wealth first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 3 quarters.
Omnia Family Wealth's Vertex Pharmaceuticals position peaked at $5K in Q1 2019.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Omnia Family Wealth's 13F filing for Q2 2019, filed 7 Aug 2019.